Vaccines: Risk for Long COVID and Vaccine Doses
A study found that 2 or 3 doses of the COVID-19 vaccine reduced the rate of long COVID among Italian health care workers.
A study found that 2 or 3 doses of the COVID-19 vaccine reduced the rate of long COVID among Italian health care workers.
To examine the infectious periods in vaccinated individuals infected with the SARS-CoV-2 Omicron and Delta variants, researchers collected daily PCR tests from a group of college students and staff.
A 50 µg dose of Moderna's bivalent booster candidate, mRNA-1273.214, demonstrated superior neutralizing antibody response against the Omicron variant one month after administration when compared to the original mRNA-1273 vaccine.
The health and economic impact of the Pfizer-BioNTech vaccine during its first year of rollout in the US is described in a new study in the peer-reviewed Journal of Medical Economics.
Read MoreWhile COVID vaccine-induced neutralizing antibody responses protect against SARS-CoV-2 infection, control of viral replication is mediated by responses that involve T cells and the antibody-binding Fc receptor.
Read MoreThe FDA limited authorized use of the J&J Janssen COVID-19 vaccine to certain individuals due to risk of thrombosis with thrombocytopenia syndrome.
Read MoreA Phase 2 clinical trial to evaluate second COVID booster shots has begun enrolling adult participants in the United States. The COVID-19 Variant Immunologic Landscape (COVAIL) trial, sponsored by the NIAID, aims to understand if different vaccine regimens—prototype and variant vaccines alone and in combinations—can broaden immune responses in adults who already have received a primary vaccination series and a first booster shot.
Read MorePfizer Inc and BioNTech SE have submitted an application for US FDA authorization of a 10-µg booster dose of its pediatric COVID booster for children age 5 through 11 years old.
Read MoreModerna’s first bivalent COVID vaccine booster candidate, mRNA-1273.211, demonstrated superior neutralizing titers compared to mRNA-1273 against all variants of concern, including Omicron.
Read MoreA clinical trial by the NIAID will study rare but potentially serious systemic allergic reactions to COVID vaccines.
Read MoreA large increase in skin bacteria in mice inoculated with the smallpox vaccine may enhance the immune response, according to a study published in Plos Pathogens.
Read MoreA 10-µg dose (third dose) of the Pfizer pediatric booster in healthy children age 5 through 11...
Read MoreThe novel CoVac-1 COVID vaccine induced T-cell immune responses in 93% of patients with B-cell deficiencies, including many patients with leukemia and lymphoma.
Read MoreResearchers at the University of Florida and National Yang Ming Chiao Tung University in Taiwan have developed a 30-second COVID test that can detect coronavirus infection in as sensitively and accurately as the gold standard PCR test.
Read MoreA third COVID vaccine dose benefitted most immunocompromised people with a blood cancer called multiple myeloma, according to a fast-tracked study in Cancer Cell.
Read More